Physician profile
Michael Yang Wang
NPI 1437189768
$5,257.63
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,273 · 2020: $478 · 2021: $237 · 2022: $672 · 2023: $308 · 2024: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564 · Education: $33.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.16 |
| Education | $33.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $867.20 | 2019-2023 | Opdivo |
| Amgen INC. | $573.34 | 2019-2022 | |
| Janssen Biotech, INC. | $413.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $377.72 | 2019-2024 | Calquence |
| Celgene Corporation | $299.13 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $273.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $265.15 | 2019-2020 | |
| Pfizer INC. | $196.79 | 2019-2022 | |
| Seagen INC. | $148.60 | 2019-2023 | Tukysa |
| Daiichi Sankyo INC. | $146.26 | 2022-2024 | Enhertu |
| Foundation Medicine, INC. | $145.51 | 2019-2022 | |
| Abbvie INC. | $138.77 | 2019-2023 | Venclexta |
| Gilead Sciences, INC. | $126.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $120.33 | 2019 | |
| Jazz Pharmaceuticals INC. | $109.67 | 2020-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108.31 | 2019-2022 | |
| Boston Scientific Corporation | $105.27 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $97.49 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $94.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.67 | 2019-2020 | |
| Kite Pharma, INC. | $86.90 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.84 | 2019-2020 | |
| Lilly USA, LLC | $61.05 | 2019-2020 | |
| Genentech USA, INC. | $45.77 | 2019-2020 | |
| Verastem, INC. | $40.49 | 2019 | |
| Tesaro, INC. | $37.25 | 2019 | |
| Taiho Oncology, INC. | $34.28 | 2019 | |
| Rigel Pharmaceuticals, INC. | $30.42 | 2022 | |
| Exelixis INC. | $28.58 | 2019 | |
| Emd Serono, INC. | $25.13 | 2019-2021 | |
| Incyte Corporation | $24.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Eisai INC. | $16.90 | 2024 | |
| Amag Pharmaceuticals, INC. | $16.49 | 2019 | |
| Advanced Accelerator Applications | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.